2. Prostate cancer is still a leading cancer killer for men in the U.S. ... 2. Just because you are diagnosed with prostate cancer, doesn't mean you need to treat it.
Researchers noted that total cancer rates were likely influenced by the increased surveillance for prostate-specific antigen and subsequent diagnoses of prostate cancer. ... The significant reduction in total cancer minus prostate cancer suggests that
One physician describes how his informed consent process was the deciding factor in a missed case of prostate cancer, and outlines how any physician can accomplish it. ... In 1990, Dr. Gottesman was sued for late diagnosis of a patient's prostate cancer.
Watchful waiting" has been most discussed as a treatment strategy for prostate cancer. ... Treatment for prostate cancer, including radical prostatectomy, is fraught with side effects that may negatively impact quality of life.
It's those patients with NASH that are at the greatest risk for progression to cirrhosis or liver cancer, and so those are the ones we want to identify and develop ... Drawbacks include a potential increase in all-cause mortality with vitamin E
QD: News Every Day--Cancer rates rise by 75% even as specific types of disease fall. ... Results appeared in The Lancet Oncology on June 1. Worldwide, rates of colorectal cancer, female breast cancer, female lung cancer and prostate cancer will rise in
Preventative Services Task Force against using the PSA blood test to screen for prostate cancer has left many patients confused, and many doctors unsurprised. ... We've known for a while that in the aggregate, the data do not show that screening for
Prostate cancer screening leads to unneeded treatments, “ ACP InternistWeekly, March 24. ... And a comment from the body of the article is revealing: “The cumulative death rate from prostate cancer at 10 years in the two groups combined was 25% lower
An Annals of Internal Medicine editorial in the May 5 issue again notes that, “Within 10 years of trial entry, screening increases the number of cancer cases diagnosed but has no ... by overzealous therapies and like to pronounce themselves as
An expanded approval of abiraterone acetate (Zytiga) to treat metastatic castration-resistant prostate cancer prior to chemotherapy. ... The drug was initially approved in November 2011 for use in patients whose prostate cancer progressed after treatment